Tobira Therapeutics Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.67B
Tobira Therapeutics General Information
Description
Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652 and TBR-220 antagonists for the treatment of HIV or AIDS, hepatitis and related infectious conditions.
Contact Information
Website
www.tobiratx.comCorporate Office
- 701 Gateway Boulevard
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 701 Gateway Boulevard
- Suite 300
- South San Francisco, CA 94080
- United States
Tobira Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 01-Nov-2016 | $1.67B | Completed | Generating Revenue | ||
| 7. Reverse Merger | 05-May-2015 | Completed | Clinical Trials - Phase 3 | |||
| 6. IPO | Cancelled | Clinical Trials - Phase 3 | ||||
| 5. Later Stage VC | 09-Mar-2015 | Completed | Clinical Trials - Phase 3 | |||
| 4. Debt - General | 30-Jun-2014 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC (Series B) | 30-Jul-2012 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 29-Sep-2010 | $21.2M | $52.2M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Aug-2007 | $31M | $31M | Completed | Product Development |
Tobira Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Tobira Therapeutics Comparisons
Industry
Financing
Details
Tobira Therapeutics Competitors (65)
One of Tobira Therapeutics’s 65 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| UCB | Corporation | Brussels, Belgium | ||||
| Galecto | Formerly VC-backed | Copenhagen, Denmark | ||||
| RedHill Biopharma | Formerly VC-backed | Tel Aviv, Israel |
Tobira Therapeutics Patents
Tobira Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10301287-B2 | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | Active | 31-Aug-2016 | ||
| AU-2017321594-A1 | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | Inactive | 31-Aug-2016 | ||
| EP-3506896-A1 | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | Inactive | 31-Aug-2016 | ||
| JP-2022137223-A | Solid form of senicrivirocumesylate and process for producing solid form of senicrivirocumesylate | Pending | 31-Aug-2016 | ||
| CA-3034606-A1 | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | Inactive | 31-Aug-2016 | C07D403/12 |
Tobira Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tobira Therapeutics Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ATEM Capital | Venture Capital | Minority | ||
| Abingworth | Venture Capital | Minority | ||
| Andera Partners | PE/Buyout | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Canaan Partners | Venture Capital | Minority |
Tobira Therapeutics Acquisitions (1)
Tobira Therapeutics’s most recent deal was a Merger/Acquisition with Regado Biosciences. The deal was made on 05-May-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Regado Biosciences | 05-May-2015 | Merger/Acquisition | Biotechnology |
Tobira Therapeutics FAQs
-
When was Tobira Therapeutics founded?
Tobira Therapeutics was founded in 2006.
-
Where is Tobira Therapeutics headquartered?
Tobira Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Tobira Therapeutics?
Tobira Therapeutics has 20 total employees.
-
What industry is Tobira Therapeutics in?
Tobira Therapeutics’s primary industry is Pharmaceuticals.
-
Is Tobira Therapeutics a private or public company?
Tobira Therapeutics is a Private company.
-
What is the current valuation of Tobira Therapeutics?
The current valuation of Tobira Therapeutics is .
-
What is Tobira Therapeutics’s current revenue?
The current revenue for Tobira Therapeutics is .
-
How much funding has Tobira Therapeutics raised over time?
Tobira Therapeutics has raised $90.2M.
-
Who are Tobira Therapeutics’s investors?
ATEM Capital, Abingworth, Andera Partners, BVF Partners, and Canaan Partners are 5 of 14 investors who have invested in Tobira Therapeutics.
-
Who are Tobira Therapeutics’s competitors?
Arrowhead Pharmaceuticals, Cytokinetics, UCB, Galecto, and RedHill Biopharma are some of the 65 competitors of Tobira Therapeutics.
-
When was Tobira Therapeutics acquired?
Tobira Therapeutics was acquired on 01-Nov-2016.
-
Who acquired Tobira Therapeutics?
Tobira Therapeutics was acquired by Allergan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
